On October 8, 2025, Apogee Therapeutics, Inc. announced an agreement to sell 6,951,221 shares of common stock at $41.00 each, raising about $323.3 million, and completed a full exercise of an option for an additional 1,097,561 shares on October 9, 2025. The offering is expected to close on October 10, 2025, and includes updates on patient enrollment for their APG777 clinical trials.